Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT Study)

Japanese Journal of Clinical Oncology

Volumn 43, Issue 7, 2013, Pages 752-755

  Nakamura, Kenichi ^a   Kato, Ken ^b   Igaki, Hiroyasu ^b   Ito, Yoshinori ^b   Mizusawa, Junki ^a   Ando, Nobutoshi ^c   Udagawa, Harushi ^d   Tsubosa, Yasuhiro ^e   Daiko, Hiroyuki ^f   Hironaka, Shuichi ^g   Fukuda, Haruhiko ^a   Kitagawa, Yuko ^h  

^a NATIONAL CANCER CENTER   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c TOKYO DENTAL COLLEGE   (Japan)

^d TORANOMON HOSPITAL   (Japan)

^e SHIZUOKA CANCER CENTER   (Japan)

^f NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^g CHIBA CANCER CENTER   (Japan)

^h KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Clinical trial; Esophageal cancer; Phase III; Preoperative chemoradiotherapy; Preoperative chemotherapy

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL;

ADULT; ADVANCED CANCER; ADVERSE OUTCOME; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG SAFETY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS; ESOPHAGUS RESECTION; FEMALE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; NOTE; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PREOPERATIVE RADIOTHERAPY; PREOPERATIVE TREATMENT; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

CLINICAL TRIAL; ESOPHAGEAL CANCER; PHASE III; PREOPERATIVE CHEMORADIOTHERAPY; PREOPERATIVE CHEMOTHERAPY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; INDUCTION CHEMOTHERAPY; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PATIENT SELECTION; RADIOTHERAPY, ADJUVANT; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 84880173368     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyt061     Document Type: Note

References (9)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Ando N. Progress in multidisciplinary treatment for esophageal cancer in Japan as reflected in JCOG studies. Esophagus 2011;8:151-7.
3. Ando N, Iizuka T, Ide H, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study-JCOG9204. J Clin Oncol 2003;21:4592-6.
4. Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol 2012;19:68-74.
5. Gebski V, Burmeister B, Smithers BM, et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007;8:226-34.
6. Kitagawa Y, Ando N, Nakamura K, et al. The role of adjuvant chemotherapy for localized squamous cell esophageal cancer: current Japanese standard and the unending role of the drawing board. Ann Surg Oncol 2012;19:1425-7.
7. Hara H, Daiko H, Kato K, et al. Final results of feasibility study of neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil (DCF) for clinical stage II/III esophageal squamous cell carcinoma. J Clin Oncol 2011;29:(Suppl) (Abstract 4060).
8. Nakamura K, Shibata T, Takashima A, et al. Evaluation of three definitions of progression-free survival in preoperative cancer therapy (JCOG0801-A). Jpn J Clin Oncol 2012;42:896-902.
9. Schoenfeld DR, Richter J. Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. Biometrics 1982;38:163-70.